Moderna has recently been the subject of various significant events and developments. The
biotech company is partnering with
Recordati on a
rare disease mRNA therapy, potentially earning them up to $160M. This development follows the departure of Moderna's
medical chief, a hiatus in their
vaccine trial investment influenced by the US backlash, and the observance of immunogenicity in a
mRNA cancer vaccine after a five-year follow-up.
Bayer's Monsanto has sued COVID vaccine manufacturers for purported
mRNA infringement, while Moderna simultaneously offloads a
late-stage rare disease drug. They've also experienced a flurry of
changes in their stock holdings and company leadership. The effectiveness of Moderna's
mRNA flu vaccine has resulted in a boost in their shares, while the departure of their latest
CMO after barely a year leaves questions. Despite uncertainties, the company has exhibited promising efficacy results from a
mRNA flu vaccine trial, and they've opened a
Moderna mRNA Vaccine Centre in Oxfordshire. Maintaining their focus on innovation, Moderna plans to develop several new products, even as they reportedly cancel other
mRNA vaccines.
Moderna MRNA News Analytics from Sat, 24 May 2025 07:00:00 GMT to Sat, 31 Jan 2026 12:01:58 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -5
